Nebula Research & Development LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Nebula Research & Development LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 4,531 shares of the medical research company's stock, valued at approximately $1,181,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Centricity Wealth Management LLC bought a new stake in Amgen in the 4th quarter valued at about $25,000. Ritter Daniher Financial Advisory LLC DE increased its holdings in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after acquiring an additional 51 shares in the last quarter. Synergy Investment Management LLC bought a new stake in shares of Amgen during the fourth quarter valued at approximately $34,000. Atala Financial Inc acquired a new position in shares of Amgen during the fourth quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC bought a new position in shares of Amgen in the 4th quarter worth $36,000. 76.50% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP David M. Reese sold 8,711 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the sale, the executive vice president now owns 62,147 shares in the company, valued at $18,222,743.34. This trade represents a 12.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on AMGN shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $324.00 price objective on shares of Amgen in a research note on Friday, January 24th. Morgan Stanley raised their target price on Amgen from $328.00 to $330.00 and gave the company an "equal weight" rating in a report on Wednesday, April 9th. Piper Sandler Companies reiterated an "overweight" rating and issued a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Cantor Fitzgerald began coverage on shares of Amgen in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 price objective for the company. Finally, Piper Sandler boosted their price objective on Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Amgen currently has a consensus rating of "Hold" and an average price target of $310.57.

Amgen Price Performance

AMGN stock traded up $5.47 during trading on Tuesday, hitting $288.56. The stock had a trading volume of 2,147,355 shares, compared to its average volume of 2,786,646. The company's 50-day moving average price is $301.10 and its two-hundred day moving average price is $292.08. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock has a market capitalization of $155.14 billion, a P/E ratio of 38.22, a PEG ratio of 2.63 and a beta of 0.59.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.30%. Amgen's dividend payout ratio is presently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.